Fulltext

No change in calculated creatinine clearance after tenofovir initiation among Thai patients

Gayet-Ageron, Angele ; Ananworanich, Jintanat ; Jupimai, Thidarat ; Chetchotisakd, Ploenchan ; Prasithsirikul, Wisit ; Ubolyam, Sasiwimol ; Le Braz, Michelle ; Ruxrungtham, Kiat ; Rooney, James F. ; Hirschel, Bernard

In: Journal of Antimicrobial Chemotherapy, 2007, vol. 59, no. 5, p. 1034-1037

Ajouter à la liste personnelle
    Titre
    • No change in calculated creatinine clearance after tenofovir initiation among Thai patients
    Auteur
    • Gayet-Ageron, Angele. University Hospital of Geneva, Geneva, Switzerland
    • Ananworanich, Jintanat. The HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT), Bangkok, Thailand
    • Jupimai, Thidarat. The HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT), Bangkok, Thailand
    • Chetchotisakd, Ploenchan. Khon Kaen University, Srinagarind Hospital, Khon Kaen, Thailand
    • Prasithsirikul, Wisit. Bamrasnaradura Institute, Nonthaburi, Thailand
    • Ubolyam, Sasiwimol. The HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT), Bangkok, Thailand
    • Le Braz, Michelle. University Hospital of Geneva, Geneva, Switzerland
    • Ruxrungtham, Kiat. The HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT), Bangkok, Thailand
    • Rooney, James F.. Gilead Sciences, Foster City, CA, USA
    • Hirschel, Bernard. University Hospital of Geneva, Geneva, Switzerland
    Type de document
    • Postprint
    Langue
    • Anglais
    Publié dans
    • Journal of Antimicrobial Chemotherapy, 2007, vol. 59, no. 5, p. 1034-1037. Oxford University Press
    Autre version électronique
    Identifiant OAI-PMH
    • oai:doc.rero.ch:290806
    Summary
    Objectives Thai patients have a lower average body weight than patients from western Europe or the USA. Tenofovir is largely prescribed at the standard dosage of 300 mg once daily: therefore, the per kilogram dose is higher in Thailand than in the USA. We asked the question whether this higher per kilogram dose was associated with more nephrotoxicity. Methods Thai patients from the Staccato trial were treated with tenofovir/lamivudine combined with ritonavir-boosted saquinavir. Creatinine values were measured before the start of tenofovir and then every 12 weeks. Renal function was assessed using the Cockcroft-Gault formula and the MDRD formula. To compare CLCR before and after tenofovir, the t-paired or Wilcoxon signed rank tests were used. One-way analysis of variance and Spearman's correlation coefficient were used to study CLCR longitudinally. Results CLCR remained stable after a median of 21 weeks on tenofovir (difference of +1.06 mL/min; 95% CI −2.7-4.8, P = 0.58), even among patients with underlying diseases. The mean CLCR remained stable across time (P = 0.17). Conclusions We did not find renal dysfunction on tenofovir among Thai patients included in the Staccato trial. Tenofovir could be safely prescribed at a standard dosage of 300 mg once daily in the Thai population